✦ LIBER ✦

1227 A phase 1, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in patients with relapsed or refractory solid tumours

✍ Scribed by M. von Mehren; C. Britten; P. Piesolor; K. Balogh; A. Bartok; S. Harris; X. Li; J. Galluppi; J. Barton; S. Leong

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1, open-label, dose-escalation s

✍ von Mehren, Margaret; Britten, Carolyn D.; Pieslor, Peter; Saville, Wayne; Vasso 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 229 KB

166 A phase I dose-escalation study of a

✍ A. Ricart; G. Liu; A. Tolcher; G. Schwartz; J. Harris; R. Stagg; E. Rowinsky; G. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 297 KB

A phase 1 study of lucatumumab, a fully

✍ William Bensinger; Richard T. Maziarz; Sundar Jagannath; Andrew Spencer; Simon D 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

372 A phase I dose-escalation study of t

✍ C. Weekes; P. Hedge; Y. Xin; R. Yu; H. Xiang; L. Gore; M. Beeram; R. Brachmann; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

1209 POSTER ONX 0912, a Novel Oral Prote

✍ K. Papadopoulos; D. Mendelson; A.W. Tolcher; H.A. Burris; M. Gordon; H. Wong; D. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

A dose finding, safety and pharmacokinet

✍ Soria, Jean Charles; Massard, Christophe; Lazar, Vladimir; Ozoux, Marie-Laure; M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 358 KB